Skip to main content
SpringerLink
Log in

Neurodegenerative Erkrankungen

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2022

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Beshir AS, Aadithsoorya AM, Parveen A, Sir Loon GS, Hussain N, Bharathan Menon VB (2022) Aducanumab therapy to treat alzheimer’s disease: a narrative review. Int J Alzheimers Dis 2022:9343514. Published online 2022 Mar 9

    PubMed  PubMed Central  Google Scholar 

  • AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363:2105–2115

    Article  Google Scholar 

  • Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031

    Article  PubMed  Google Scholar 

  • Bilia AR, Ceu Costa M (2021) Medicinal plants and their preparations in the European market: why has harmonization failed? The cases of St. John’s wort, valerian, ginkgo, ginseng and green tea. Phytomedicine 81:153421

    Article  PubMed  Google Scholar 

  • Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005593

    Article  PubMed  PubMed Central  Google Scholar 

  • Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003120.pub3

    Article  PubMed  Google Scholar 

  • Birks JS, Grimley Evans J (2015) Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001191.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001190.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • Budd Haeberlein S, von Hehn C, Tian Y et al (2020) Emerge and Engage topline results: phase 3 studies of aducanumab in early Alzheimer’s disease. Alzheimers Dement 16(S9):e47259

    Google Scholar 

  • Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9(2):197–210

    CAS  PubMed  Google Scholar 

  • Coarelli G, Heinzmann A, Ewenczyk C et al (2022) Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 21:225–233

    Article  CAS  PubMed  Google Scholar 

  • Cummings J (2018) Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci 11:147–152

    Article  PubMed  Google Scholar 

  • Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403

    Article  CAS  PubMed  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN) (2016) S3-Leitlinie Demenzen. http://www.dgn.org/leitlinien/3177-die-leitlinie-demenzen-2016-punkt-fuer-punkt

  • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321

    Article  CAS  PubMed  Google Scholar 

  • Escher C, Jensen F (2019) Prävention von kognitivem Abbau und Demenz durch Behandlung von Risikofaktoren. Nervenarzt 90:921–925

    Article  PubMed  Google Scholar 

  • European Medicines Agency (2021) Refusal of the marketing authorisation for Aduhelm (aducanumab)

    Google Scholar 

  • Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17:416–422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Flicker L, Grimley Evans G (2001) Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001011

    Article  PubMed  PubMed Central  Google Scholar 

  • Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223

    Article  CAS  PubMed  Google Scholar 

  • Ibrahim MA, Ramadan HH, Mohammed RN (2021) Evidence that Ginkgo biloba could use in the influenza and coronavirus COVID-19 infections. J Basic Clin Physiol Pharmacol 32:131–143

    Article  CAS  PubMed  Google Scholar 

  • Knopman DS, Jones DT, Greicius MD (2021) Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 17(4):696–701

    Article  PubMed  Google Scholar 

  • Loy C, Schneider L (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001747.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J (2019) Memantine for dementia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003154.pub6

    Article  PubMed  PubMed Central  Google Scholar 

  • Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001447.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  • Mullard A (2021) Landmark Alzheimer’s drug approval confounds research community. Nature 594(7863):309–310

    Article  CAS  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (2018) Dementia: assessment, management and support for people living with dementia and their carers. https://www.nice.org.uk/guidance/ng97. Zugegriffen: 20. Juni 2018

  • Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–2388

    Article  CAS  PubMed  Google Scholar 

  • Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379–397

    Article  PubMed  Google Scholar 

  • Ristori G, Romano S, Visconti A et al (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839–835

    Article  CAS  PubMed  Google Scholar 

  • Romano S, Coarelli G, Marcotulli C et al (2015) Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14:985–991

    Article  CAS  PubMed  Google Scholar 

  • Rosenbohm A, Peter RS, Erhardt S, Lule D, Rothenbacher D, Ludolph AC, Nagel G (2017) Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 264:749–757

    Article  PubMed  Google Scholar 

  • Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer’s disease. Lancet 388:505–517

    Article  CAS  PubMed  Google Scholar 

  • Sinha S, Barocas JA (2022) Cost-effectiveness of aducanumab to prevent Alzheimer’s disease progression at current list price. Alzheimers Dement 8(1):e12256

    Google Scholar 

  • Tsoi KK, Chan JY, Leung NW, Hirai HW, Wong SY, Kwok TC (2016) Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials. J Am Med Dir Assoc 17:863.e1–863.e8

    Article  PubMed  Google Scholar 

  • U.S. Food & Drug Administration (2021) FDA’s decision to approve new treatment for Alzheimer’s disease

    Google Scholar 

  • Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S (2012) Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11:851–859

    Article  CAS  PubMed  Google Scholar 

  • Williams ST (2021) Herbal supplements: precautions and safe use. Nurs Clin North Am 56:1–2

    Article  PubMed  Google Scholar 

  • Winblad B (2005) Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11:169–182

    Article  CAS  PubMed  Google Scholar 

  • Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS (2008) Safety and efficacy of galantamine in subjects with mild cognitive impairment. Baillieres Clin Neurol 70:2024–2035

    CAS  Google Scholar 

  • Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ahizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL (2018) Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90:464–471

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Hochschule Hannover, Institut für Pharmakologie, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    Prof. Dr. med. Roland Seifert

  2. Klinik für Neurologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    Prof. Dr. med. Susanne Petri

Authors
  1. Prof. Dr. med. Roland Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Susanne Petri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roland Seifert .

Editor information

Editors and Affiliations

  1. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Deutschland

    Wolf-Dieter Ludwig

  2. Institut für Pharmakologie, Klinikum Bremen-Mitte, Bremen, Deutschland

    Bernd Mühlbauer

  3. Institut für Pharmakologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Roland Seifert

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Seifert, R., Petri, S. (2022). Neurodegenerative Erkrankungen. In: Ludwig, WD., Mühlbauer, B., Seifert, R. (eds) Arzneiverordnungs-Report 2022. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-66303-5_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-66303-5_28

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-66302-8

  • Online ISBN: 978-3-662-66303-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation